Skip to Content
Merck
All Photos(2)

Key Documents

GF07844249

Ruthenium

Ruthenium, foil, 10x10mm, thickness 1.0mm, 99.9%

Synonym(s):

Ruthenium, RU000220

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
Ru
CAS Number:
Molecular Weight:
101.07
MDL number:
UNSPSC Code:
12141739
PubChem Substance ID:
NACRES:
NA.23

Assay

99.9%

form

foil

manufacturer/tradename

Goodfellow 078-442-49

resistivity

7.1 μΩ-cm, 0°C

L × W × thickness

10 mm × 10 mm × 1.0 mm

bp

3900 °C (lit.)

mp

2310 °C (lit.)

density

12.45 g/cm3 (lit.)

SMILES string

[Ru]

InChI

1S/Ru

InChI key

KJTLSVCANCCWHF-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow

Storage Class Code

13 - Non Combustible Solids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Martin R Gill et al.
Chemical Society reviews, 41(8), 3179-3192 (2012-02-09)
In the last few decades, coordination complexes based on d(6) metal centres and polypyridyl ligand architectures been developed as structure- and site-specific reversible DNA binding agents. Due to their attractive photophysical properties, much of this research has focused on complexes
E Tfouni et al.
Current medicinal chemistry, 17(31), 3643-3657 (2010-09-18)
The discovery of the involvement of nitric oxide (NO) in several physiological and pathophysiological processes launched a spectacular increase in studies in areas such as chemistry, biochemistry, and pharmacology. As a consequence, the development of NO donors or scavengers for
Aviva Levina et al.
Metallomics : integrated biometal science, 1(6), 458-470 (2009-11-01)
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH(+))[Ru(III)Cl(4)(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH(+))[Ru(III)Cl(4)(Ind)(2)], where Ind = indazole) have successfully completed phase I clinical trials and an array of other
A Bergamo et al.
Journal of inorganic biochemistry, 106(1), 90-99 (2011-11-25)
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with
Lutz Ackermann et al.
Topics in current chemistry, 292, 211-229 (2010-01-01)
Stoichiometric cycloruthenation reactions of substrates containing Lewis-basic functionalities set the stage for efficient ruthenium-catalyzed C-H bond functionalization reactions. Thereby, selective addition reactions of C-H bonds across alkenes or alkynes enabled atom-economical synthesis of substituted arenes. More recently, ruthenium-catalyzed direct arylation

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service